ImmunoVaccine (IMV) has notable insider buying

ImmunoVaccine (T:IMV)

Pierre Labbe, a Senior Officer, acquired 26,825 Common Shares on a direct ownership basis at a price of $1.220 through the public market on July 28th, 2017. This represents a $32,726 investment into the company's shares and an account share holdings change of 11.3%.

Alfred Smithers, a Director, acquired 100,000 Common Shares on an indirect ownership basis for registered holder Smithers International Limited at a price of $1.220 through the public market on July 24th, 2017. This represents a $122,000 investment into the company's shares and an account share holdings change of 2.8%.

Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.